Premium
Nevirapine patch testing in T hai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity
Author(s) -
Prasertvit Piyatida,
Chareonyingwattana Angkana,
Wattanakrai Penpun
Publication year - 2017
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/cod.12849
Subject(s) - nevirapine , medicine , patch test , delayed hypersensitivity , human leukocyte antigen , immunology , human immunodeficiency virus (hiv) , hla b , gastroenterology , allergy , viral load , antigen , antiretroviral therapy
Summary Background Antiretroviral drug hypersensitivity in HIV patients is common. Publications have shown that A bacavir ( ABC ) patch testing is useful in confirming ABC hypersensitivity in 24–50% of cases with a 100% sensitivity of HLA ‐ B *5701 in patch test positive cases. However, N evirapine ( NVP ) patch testing has not been reported. Objectives (1) To evaluate the usefulness and safety of NVP patch testing in T hai HIV patients with NVP hypersensitivity. (2) To assess the correlation of positive patch tests with HLA ‐ B *3505. Patients and methods Patients were classified into two groups: (1) study group of 20 HIV NVP hypersensitivity patients and (2) control group of 15 volunteers without NVP hypersensitivity. Both groups were patch tested with purified and commercialized form of NVP in various vehicles. Results Two HIV patients with NVP hypersensitivity were patch test positive. All controls tested negative. Three HIV patients were positive for HLA ‐ B *3505 and the two patients with positive patch testing were both HLA‐B *3505 positive. Conclusions NVP patch testing in T hai HIV patients is safe and can be used to help confirm the association between NVP and hypersensitivity skin reactions. NVP patch test results significantly correlated with HLA‐B *3505. The sensitivity of HLA‐B *3505 for positive patch test was 100%.